
PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.
PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.
The specialty drug market has exploded in the last few decades.
According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”
The role of health care specialty pharmacies has expanded.
From medication adherence to patient counseling, clinical pharmacists at health system specialty pharmacies can play a role in reducing health care costs.
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.
Participants of a recent study who received automated text messaging and monitoring, as well as peer support and coaching, increased PrEP uptake from 11% to over 20%.
A study presented at Digestive Disease Week 2023 compared the effectiveness of different approaches to prevent complications in individuals with the common disease.
The approval of Rinvoq (upadacitinib) was based on the results of three clinical trials: two induction therapy studies and one maintenance study.
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.